Autor(es):
Melo, Miguel ; Gaspar Da Rocha, Adriana ; Vinagre, João ; Batista, Rui ; Peixoto, Joana ; Tavares, Catarina ; Celestino, Ricardo ; Almeida, Ana ; Salgado, Catarina ; Eloy, Catarina ; Castro, Patrícia ; Prazeres, Hugo ; Lima, Jorge ; Amaro, Teresina ; Lobo, Cláudia ; Martins, Maria João ; Moura, Margarida ; Cavaco, Branca ; Leite, Valeriano ; Cameselle-Teijeiro, José ; Carrilho, Francisco ; Carvalheiro, Manuela ; Maximo, Valdemar ; Sobrinho-Simões, Manuel ; Soares, Paula
Data: 2014
Identificador Persistente: http://hdl.handle.net/10400.22/5395
Origem: Repositório Científico do Instituto Politécnico do Porto
Descrição
Context: Telomerase promoter mutations (TERT) were recently described in follicular cell-derived thyroid carcinomas (FCDTC) and seem to be more prevalent in aggressive cancers. Objectives: We aimed to evaluate the frequency of TERT promoter mutations in thyroid lesions and to investigate the prognostic significance of such mutations in a large cohort of patients with differentiated thyroid carcinomas (DTCs). Design: This was a retrospective observational study. Setting and Patients: We studied 647 tumors and tumor-like lesions. A total of 469 patients with FCDTC treated and followed in five university hospitals were included. Mean follow-up (±SD) was 7.8 ± 5.8 years. Main Outcome Measures: Predictive value of TERT promoter mutations for distant metastasization, disease persistence at the end of follow-up, and disease-specific mortality. Results: TERT promoter mutations were found in 7.5% of papillary carcinomas (PTCs), 17.1% of follicular carcinomas, 29.0% of poorly differentiated carcinomas, and 33.3% of anaplastic thyroid carcinomas. Patients with TERT-mutated tumors were older (P < .001) and had larger tumors (P = .002). In DTCs, TERT promoter mutations were significantly associated with distant metastases (P < .001) and higher stage (P < .001). Patients with DTC harboring TERT promoter mutations were submitted to more radioiodine treatments (P = .009) with higher cumulative dose (P = .004) and to more treatment modalities (P = .001). At the end of follow-up, patients with TERT-mutated DTCs were more prone to have persistent disease (P = .001). TERT promoter mutations were significantly associated with disease-specific mortality [in the whole FCDTC (P < .001)] in DTCs (P < .001), PTCs (P = .001), and follicular carcinomas (P < .001). After adjusting for age at diagnosis and gender, the hazard ratio was 10.35 (95% confidence interval 2.01–53.24; P = .005) in DTC and 23.81 (95% confidence interval 1.36–415.76; P = .03) in PTCs. Conclusions: TERT promoter mutations are an indicator of clinically aggressive tumors, being correlated with worse outcome and disease-specific mortality in DTC. TERT promoter mutations have an independent prognostic value in DTC and, notably, in PTC.
